Skip to main content

Table 1 Demographic data

From: Adverse effect of increased left ventricular wall thickness on five year outcomes of patients with negative dobutamine stress

   

LV EDWT

LV EDWT

p-value

 

Total

 

≤12 mm

 

>12 mm

  
 

n = 175

n = 98

n = 77

 

Patient Characteristics

       

   Age (yrs)

69

(± 12)

65

(± 15)

71

(± 10)

0.013

   Gender Women, Men

102

73.0

63

35.0

39

38.0

0.07

   Weight (kg)

92.2

(± 23.4)

90.6

(± 23.0)

94.3

(± 23.7)

0.32

   BSA (m2)

2.3

(± 0.7)

2.1

(± 0.7)

2.4

(± 0.8)

0.56

   Wall Thickness

12.3

(± 3.1)

9.2

(± 0.8)

16.0

(± 2.4)

0.0001

Historical Information

       

   Prior CAD

81

(50.0%)

41

(41.8%)

40

(51.9%)

0.190

   Prior Revascularization

28

(16.0%)

10

(10.2%)

18

(23.4%)

0.018

   Hypertension

112

(64.0%)

52

(53.1%)

60

(77.9%)

0.0006

   Diabetes Melitus

51

(29.1%)

23

(23.5%)

28

(36.4%)

0.063

   Hyperlipidemia

89

(50.9%)

46

(46.9%)

43

(55.8%)

0.240

   Smoking

64

(36.6%)

31

(31.6%)

33

(42.9%)

0.130

   Asthma/COPD

39

(22.3%)

16

(16.3%)

23

(29.9%)

0.033

Medications

       

   Digoxin

9

(5.1%)

6

(6.1%)

3

(3.9%)

0.51

   Vasodilator

14

(8.0%)

7

(7.1%)

28

(36.4%)

0.64

   Diuretic

60

(34.3%)

32

(32.7%)

28

(36.4%)

0.61

   Beta Blocker

54

(30.9%)

23

(23.5%)

31

(40.3%)

0.017

   Calcium Antagonist

32

(18.3%)

13

(13.3%)

19

(24.7%)

0.053

   ASA

82

(46.9%)

43

(43.9%)

39

(50.6%)

0.38

   Nitrate

45

(25.7%)

20

(20.4%)

25

(32.5%)

0.071

   ACE Inhibitor

39

(22.3%)

16

(16.3%)

23

(29.9%)

0.033

   Anti-Coagulation

15

(8.6%)

4

(4.1%)

11

(14.3%)

0.017

   Statin

65

(37.1%)

28

(28.6%)

37

(48.1%)

0.0079

  1. Abbreviations: ACE, angiotensin converting enzyme; ASA, aspirin, BSA; body surface area; CAD, coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive airways disease, LV EDWT, left ventricular end-diastolic wall thickness.